Mylan In Australia

Mylan entered the Australian market in 2007, following its acquisition of Alphapharm, a company supplying generic medicines in Australia since 1982. Together, we have built on this legacy in providing patients greater access to affordable medicine in Australia and around the world.

Mylan in Australia is the leading supplier of medicines by volume to the Pharmaceutical Benefits Scheme (PBS)*. One in seven PBS prescriptions dispensed is a Mylan medicine.* This contributes to the sustainability of the PBS by providing timely access for patients to quality, safe, efficacious and affordable medicines.

In 2015, we continued our expansion by further increasing our healthcare portfolio in Australia.

We locally produce more than 200 quality medicines, making us one of the largest pharmaceutical manufacturers in the country. Our internationally accredited manufacturing plant at Carole Park, Queensland, will produce close to 3 billion doses of oral solid dose medicine in 2016, more than half of which will be exported to about 50 countries.

Our medicines are made to high quality standards, meeting the regulatory requirements of the Therapeutic Goods Administration (TGA), the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA).

*Expenditure and prescriptions 12 months to 30 June 2015. Pharmaceutical Benefits Scheme. Available at: Pharmaceutical Benefits Scheme website

Mylan in Australia at a Glance

  • 1 in 7 prescriptions dispensed is  a Mylan medicine*

  • Alphapharm has supplied generic and branded medicines in Australia for over 30 years

  • Mylan acquired Alphapharm in 2007

  • Carole Park plant will produce close to 3 billion doses in 2016.

  • Export to approximately 50 countries

  • In 2015, Mylan further expands our branded products portfolio via acquisition of Abbott's Non-U.S. Developed Markets Specialty and Branded Generics business.
Last Updated  5/08/2016